Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients

MLA

Mhairi Copland, et al. “Randomized Evaluation of Quizartinib and Low-Dose Ara-C vs Low-Dose Ara-C in Older Acute Myeloid Leukemia Patients.” Blood Advances, vol. 5, no. 24, Dec. 2021, pp. 5621–25. EBSCOhost, widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....947c8117ccc63e5664af5a159d9fb5a5&authtype=sso&custid=ns315887.

APA

Mhairi Copland, Ian Thomas, Nigel H. Russell, Richard E. Clark, Robert Kerrin Hills, Cono Ariti, Priyanka Mehta, Michael Dennis, Steven Knapper, Laura Upton, Rohini Radia, Amanda F. Gilkes, Claire Hemmaway, & Alan K. Burnett. (2021). Randomized evaluation of quizartinib and low-dose ara-C vs low-dose ara-C in older acute myeloid leukemia patients. Blood Advances, 5(24), 5621–5625.

Chicago

Mhairi Copland, Ian Thomas, Nigel H. Russell, Richard E. Clark, Robert Kerrin Hills, Cono Ariti, Priyanka Mehta, et al. 2021. “Randomized Evaluation of Quizartinib and Low-Dose Ara-C vs Low-Dose Ara-C in Older Acute Myeloid Leukemia Patients.” Blood Advances 5 (24): 5621–25. http://widgets.ebscohost.com/prod/customlink/proxify/proxify.php?count=1&encode=0&proxy=&find_1=&replace_1=&target=https://search.ebscohost.com/login.aspx?direct=true&site=eds-live&scope=site&db=edsair&AN=edsair.doi.dedup.....947c8117ccc63e5664af5a159d9fb5a5&authtype=sso&custid=ns315887.